Literature DB >> 18314293

Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006).

Mariana Castanheira1, Ronald N Jones, Hélio S Sader.   

Abstract

Gram-positive bacterial strains (6710) consecutively collected during 2006 in hospitals located in the United States and Canada were tested by reference broth microdilution methods against daptomycin and comparison agents. Only 1 Staphylococcus aureus strain (0.01%) had nonsusceptible daptomycin MIC value as specified by published break points. S. aureus daptomycin MIC distributions from 2006 as compared with those of previous years did not show "MIC creep". Resistance to other compounds, such as vancomycin, oxacillin, and penicillin, did not adversely influence daptomycin activity. Daptomycin remains highly active against clinical Gram-positive isolates collected in North America.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18314293     DOI： 10.1016/j.diagmicrobio.2008.01.016

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  15 in total

1.  Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.

Authors:  Molly E Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Molly Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

3.  Prospective, open-label investigation of the pharmacokinetics of daptomycin during cardiopulmonary bypass surgery.

Authors:  Megan H Nguyen; Samantha J Eells; Jennifer Tan; Corinne T Sheth; Bassam Omari; Margarita Flores; Jeffrey Wang; Loren G Miller
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

Review 4.  It's not easy being green: the viridans group streptococci, with a focus on pediatric clinical manifestations.

Authors:  Christopher D Doern; Carey-Ann D Burnham
Journal:  J Clin Microbiol       Date:  2010-09-01       Impact factor: 5.948

5.  [Daptomycin for the treatment of gram-positive infections after cardiac surgery].

Authors:  B Luchting; F Weis; J Heyn; A Beiras-Fernandez
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-11-14       Impact factor: 0.840

6.  Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.

Authors:  Molly E Steed; Brian J Werth; Cortney E Ireland; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

7.  Identification of a novel clone, ST736, among Enterococcus faecium clinical isolates and its association with daptomycin nonsusceptibility.

Authors:  Guiqing Wang; Sitharthan Kamalakaran; Abhay Dhand; Weihua Huang; Caroline Ojaimi; Jian Zhuge; Leslie Lee Yee; Pramod Mayigowda; Pavan Kumar Makam Surendraiah; Nevenka Dimitrova; John T Fallon
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

8.  In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers.

Authors:  Aryun Kim; Larry A Suecof; Christina A Sutherland; Lihong Gao; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2008-09-08       Impact factor: 5.191

9.  The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas.

Authors:  P E Pertel; B I Eisenstein; A S Link; B Donfrid; E J A Biermann; P Bernardo; W J Martone
Journal:  Int J Clin Pract       Date:  2009-03       Impact factor: 2.503

10.  Hospital-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) in Italy.

Authors:  Floriana Campanile; Dafne Bongiorno; Sonia Borbone; Stefania Stefani
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-06-24       Impact factor: 3.944
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.